https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32265 Tue 25 Jul 2023 12:50:05 AEST ]]> Investigation of the molecular mechanisms underlying estrogen-mediated induction of vitellogenin gene expression in the Sydney rock oyster, Saccostrea glomerata https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29100 Thu 26 Jul 2018 13:14:56 AEST ]]> Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25887 Thu 21 Jul 2022 15:37:04 AEST ]]> Potential mechanisms underlying estrogen-induced expression of the molluscan estrogen receptor (ER) gene https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29784 sgER) and the 5'-flanking region of the gene from the Sydney rock oyster Saccostrea glomerata. The sgER cDNA is predicted to encode a 477-amino acid protein that contains a DNA-binding domain (DBD) and a ligand-binding domain (LBD) typically conserved among both vertebrate and invertebrate ERs. A comparison of the sgER LBD sequence with those of other ligand-dependent ERs revealed that the sgER LBD is variable at several conserved residues known to be critical for ligand binding and receptor activation. Ligand binding assays using fluorescent-labelled E2 and purified sgER protein confirmed that sgER is devoid of estrogen binding. In silico analysis of the sgER 5'-flanking sequence indicated the presence of three putative estrogen responsive element (ERE) half-sites and several putative sites for ER-interacting transcription factors, suggesting that the sgER promoter may be autoregulated by its own gene product. sgER mRNA is ubiquitously expressed in adult oyster tissues, with the highest expression found in the ovary. Ovarian expression of sgER mRNA was significantly upregulated following in vitro and in vivo exposure to 17β-estradiol (E2). Notably, the activation of sgER expression by E2 in vitro was abolished by the specific ER antagonist ICI 182, 780. To determine whether sgER expression is epigenetically regulated, the in vivo DNA methylation status of the putative proximal promoter in ovarian tissues was assessed using bisulfite genomic sequencing. The results showed that the promoter is predominantly hypomethylated(with 0–3.3% methylcytosines) regardless of sgER mRNA levels. Overall, our investigations suggest thatthe estrogen responsiveness of sgER is regulated by a novel ligand-dependent receptor, presumably via a non-genomic pathway(s) of estrogen signalling.]]> Thu 14 Sep 2017 11:29:22 AEST ]]> Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-Year update of International Breast Cancer Study Group Trial 11-93 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7415 Sat 24 Mar 2018 08:40:26 AEDT ]]> Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13280 Sat 24 Mar 2018 08:15:16 AEDT ]]> Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:11170 Sat 24 Mar 2018 08:10:42 AEDT ]]> The constitutively active estrogen receptor (ER) binds and activates the promoter of the vitellogenin (Vtg) gene in the Sydney rock oyster, Saccostrea glomerata https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34582 Fri 29 Mar 2019 11:40:28 AEDT ]]>